Abstract
Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.
| Original language | English |
|---|---|
| Pages (from-to) | 611-621 |
| Number of pages | 11 |
| Journal | Drug Design, Development and Therapy |
| Volume | 13 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- epigallocatechin-3-gallate
- hepatocellular carcinoma
- preclinical studies
- tumor progression
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science
- Drug Discovery
Cite this
Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma : experimental findings and translational perspectives. / Bimonte, Sabrina; Albino, Vittorio; Piccirillo, Mauro; Nasto, Aurelio; Molino, Carlo; Palaia, Raffaele; Cascella, Marco.
In: Drug Design, Development and Therapy, Vol. 13, 01.01.2019, p. 611-621.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma
T2 - experimental findings and translational perspectives
AU - Bimonte, Sabrina
AU - Albino, Vittorio
AU - Piccirillo, Mauro
AU - Nasto, Aurelio
AU - Molino, Carlo
AU - Palaia, Raffaele
AU - Cascella, Marco
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.
AB - Hepatocellular carcinoma (HCC), a primary liver malignancy, is one of the deadliest cancers worldwide. Despite orthotopic liver transplantation and hepatic resection representing the principal lines of treatment for this pathology, only a minority of patients can be resected owing to cirrhosis or late diagnosis. Keeping in mind the end goal of conquering these challenges, new alternative approaches have been proposed. Accumulating evidence has demonstrated that epigallocatechin-3-gallate (EGCG), the principal catechin of green tea with multiple biological properties, is able to modulate different molecular mechanisms underlying HCC, mainly through its antioxidant activity. In this article, we revise these findings reported in the literature, in order to highlight the potential roles of EGCG in the treatment of HCC. The CAMARADES criteria were applied for quality assessment of animal studies, and a narrative synthesis performed. New bits of information available for translational perspectives into clinical practice are addressed.
KW - epigallocatechin-3-gallate
KW - hepatocellular carcinoma
KW - preclinical studies
KW - tumor progression
UR - http://www.scopus.com/inward/record.url?scp=85062820296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062820296&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S180079
DO - 10.2147/DDDT.S180079
M3 - Review article
C2 - 30858692
AN - SCOPUS:85062820296
VL - 13
SP - 611
EP - 621
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
SN - 1177-8881
ER -